Humacyte, Inc.
HUMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 23.9% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -427.5% | -4,756.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -4,879.7% | -5,777.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -764.5% | -2,096.4% |
| EPS Diluted | -1.26 | -1.07 | -0.12 | -0.66 |
| % Growth | -17.8% | -791.7% | 81.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |